Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.

ABSTRACT:

Background

Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most cancers increases with age, new drugs should also be evaluated in older patients to assess their safety and efficacy. The EGALICAN-2 study was primarily designed to identify social and/or regional inequalities regarding access to ECT. We focused on the factors of inequalities in access to ECT in older patients.

Patients and methods

During a 1-year period (2015-2016), a survey was conducted in 11 early-phase units certified by the French National Cancer Institute.

Results

A total of 1319 patients were included in the analyses: 1086 patients (82.3%) were <70 years and 23

SUBMITTER: Baldini C 

PROVIDER: S-EPMC9271476 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature